

**Appendix 8: Methodological quality of randomized controlled trials of long-acting insulin analogues in type 1 diabetes.**

Study*	Jadad score for:			Total Jadad score	Allocation Concealment?	Blinding of Outcome Assessor?	Intent-to- Treat analysis?	Number of Patients	Dropouts N (%)
	Randomization	Double Blinding	Withdrawals and Dropouts						
Ashwell <i>et al.</i> , 2006 <sup>93</sup>	2	0	1	3	Adequate	No	No	54	3 (5.6)
De Leeuw <i>et al.</i> , 2005 <sup>115</sup>	1	0	1	2	Unclear	NR	Yes	315	8 (2.53)
Fulcher <i>et al.</i> , 2005 <sup>116</sup>	1	0	1	2	Unclear	Partially	Yes	125	18 (14.4)
Hermansen <i>et al.</i> , 2001 <sup>117</sup>	1	0	1	2	Unclear	Partially	No	59	3 (5.1)
Hermansen <i>et al.</i> , 2004 <sup>95</sup>	1	0	1	2	Unclear	No	Yes	595	23 (3.87)
Hershon <i>et al.</i> , 2004 <sup>118</sup>	1	0	1	2	Unclear	NR	Yes	394	40 (10.2)
Home <i>et al.</i> , 2005 <sup>119</sup>	2	0	1	3	Unclear	NR	Yes	585	37 (6.32)
Home <i>et al.</i> , 2004 <sup>120</sup>	2	0	1	3	Unclear	NR	Yes	408	17(4.2)
Kolendorf <i>et al.</i> , 2006 <sup>90</sup>	1	0	1	2	Unclear	No	No	131	7 (5.34)
Kudva <i>et al.</i> , 2005 <sup>122</sup>	2	0	1	3	Adequate	Partially	No	24	2 (8.33)
Murphy <i>et al.</i> , 2003 <sup>96</sup>	1	0	1	2	Unclear	No	No	26	1 (3.85)
Pieber <i>et al.</i> , 2000 <sup>112</sup>	1	0	1	2	Unclear	NR	NR	333	0 (0)
Pieber <i>et al.</i> , 2005 <sup>123</sup>	2	0	1	3	Unclear	NR	Yes	400	21 (5.25)
Pieber <i>et al.</i> , 2007 <sup>141</sup>	1	0	1	2	Adequate	No	No	320	29(9.0)

Study*	Jadad score for:			Total Jadad score	Allocation Concealment?	Blinding of Outcome Assessor?	Intent-to- Treat analysis?	Number of Patients	Dropouts N (%)
	Randomization	Double Blinding	Withdrawals and Dropouts						
Porcellati <i>et al.</i> , 2004 <sup>124</sup>	2	0	0	2	Adequate	NR	Yes	121	0 (0)
Raskin <i>et al.</i> , 2000 <sup>113</sup>	2	0	1	3	Unclear	NR	NR	619	31 (5)
Ratner <i>et al.</i> , 2000 <sup>125</sup>	1	0	1	2	Unclear	NR	Yes	534	53 (9.93)
Robertson <i>et al.</i> , 2007 <sup>97</sup>	1	0	1	2	Adequate	No	Yes	347	12 (3.46)
Rosenstock <i>et al.</i> , 2000 <sup>126</sup>	1	0	1	2	Unclear	NR	Yes	256	2 (0.78)
Rossetti <i>et al.</i> , 2003 <sup>130</sup>	1	0	0	1	Unclear	NR	NR	51	NR
Russell-Jones <i>et al.</i> , 2004 <sup>133</sup>	2	0	1	3	Unclear	NR	Yes	749	49 (6.54)
Schober <i>et al.</i> , 2002 <sup>134</sup>	1	0	0	1	Unclear	NR	Yes	361	12 (3.32)
Standl <i>et al.</i> , 2004 <sup>135</sup>	1	0	1	2	Unclear	NR	Yes	289	37 (12.8)
Vague <i>et al.</i> , 2003 <sup>136</sup>	2	0	1	3	Unclear	NR	Yes	447	22 (4.92)
Witthaus <i>et al.</i> , 2001 <sup>137</sup>	2	0	0	2	Unclear	NR	Yes	517	NR

NR=not reported

\*Citations of the studies are listed in the main article, available at [www.cmaj.ca/cgi/content/full/180/4/385](http://www.cmaj.ca/cgi/content/full/180/4/385).